Changing impact of cytomegalovirus in liver transplantation - A single centre experience of more than 1000 transplantations without ganciclovir prophylaxis

Transplant International

Volumn 18, Issue 8, 2005, Pages 941-948

  Seehofer, Daniel ^a,b   Rayes, Nada ^a   Neumann, Ulf P ^a   Meisel, Helga ^a   Oettle, Helmut ^a   Nüssler, Natascha C ^a   Jonas, Sven ^a   Langrehr, Jan M ^a   Neuhaus, Peter ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antiviral treatment; Cytomegalovirus; Ganciclovir; Liver transplantation; pp65 antigen test; Prophylaxis; Risk factors

Indexed keywords

GANCICLOVIR; STEROID; ANTIVIRUS AGENT; VIRUS ANTIBODY;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; CONTROLLED STUDY; CYTOMEGALIC INCLUSION BODY DISEASE; ERYTHROCYTE CONCENTRATE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MORTALITY; MULTIVARIATE ANALYSIS; PNEUMONIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL; BLOOD; FEMALE; GRAFT SURVIVAL; INCIDENCE; MALE;

ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; GRAFT SURVIVAL; HUMANS; INCIDENCE; LIVER TRANSPLANTATION; MALE; RISK FACTORS;

EID: 25144450133     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2005.00162.x     Document Type: Article

References (27)

1. Paya CV, Wiesner RH, Hermans PE, et al. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. J Hepatol 1993; 18: 185.
2. Kanj SS, Sharara AI, Clavien PA, Hamilton JD. Cytomegalovirus infection following liver transplantation: review of the literature. Clin Infect Dis 1996; 22: 537.
3. Stratta RJ, Shaeffer MS, Markin RS, et al. Cytomegalovirus infection and disease after liver transplantation. Dig Dis Sci 1992; 37: 673.
4. Gorensek MJ, Carey WD, Vogt D, Goormastic M. A multivariate analysis of risk factors for cytomegalovirus infection in liver transplant recipients. Gastroenterology 1990; 98: 1326.
5. Paya CV, Hermans PE, Washington JA, et al. Incidence, distribution and outcome of episodes of infection in 100 orthotopic liver transplantations. Mayo Clin Proc 1989; 64: 655.
6. Falagas ME, Snydman DR, Griffith J, Ruthazer R, Werner BG. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. Ann Intern Med 1997; 126: 275.
7. de Otero J, Gavaldà J, Murio E, et al. Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation. Clin Infect Dis 1998; 26: 865.
8. Martin M, Manez R, Linden P, et al. A prospective randomized trial comparing sequential ganciclovir - high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1994; 58: 779.
9. Dunn DL, Gillingham KJ, Kramer MA, et al. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. Transplantation 1994; 57: 876.
10. Sampathkumar P, Paya CV. Management of cytomegalovirus infection after liver transplantation. Liver Transpl 2000; 6: 144.
11. Schmidt CA, Oettle H, Peng R, et al. Comparison of polymerase chain reaction from plasma and buffy coat with antigen detection and occurrence of immunoglobulin M for the demonstration of cytomegalovirus infection after liver transplantation. Transplantation 1995; 59: 1133.
12. Seehofer D, Meisel H, Rayes N, et al. Prospective evaluation of the clinical utility of different methods for the detection of HCMV disease after liver transplantation. Am J Transplant 2004; 4: 1331.
13. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus i.v. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients. Transplantation 2000; 70: 717.
14. Ljungman P, Griffiths P, Paya C: Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094.
15. Rayes N, Oettle H, Schmidt CA, et al. Preemptive therapy in CMV-antigen positive patients after liver transplantation - a prospective trial. Ann Transplant 1999; 4: 12.
16. Rayes N, Seehofer D, Schmidt CA, et al. Prospective randomized trial to assess the value of preemptive oral therapy for CMV-infection following liver transplantation. Transplantation 2001; 72: 881.
17. Badley AD, Seaberg EC, Porayko MK, et al. Prophylaxis of cytomegalovirus infection in liver transplantation. Transplantation 1997; 64: 66.
18. Gane E, Saliba F, Valdecasas GJ, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver transplant recipients. Lancet 1997; 350: 1729.
19. Tzakis AG. Cytomegalovirus prophylaxis with ganciclovir and cytomegalovirus immune globulin in liver and intestinal transplantation. Transpl Infect Dis 2001; 3 (Suppl. 2): 35.
20. Winston DJ, Busuttil RW. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Transplantation 2003; 75: 229.
21. Kornberg A, Grube T, Homann M, Schotte U, Scheele J. Cytomegalovirus infection after liver transplantation using different prophylaxes. Transplant Proc 2001; 33: 3624.
22. Paya CV, Wilson JA, Espy MJ, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant recipients: a randomized, placebo-controlled trial. J Infect Dis 2002; 185: 854.
23. Singhal S, Khan OA, Bramble RA, Mutimer DJ. Cytomegalovirus disease following liver transplantation: an analysis of prophylactic strategies. J Infect 2003; 47: 104.
24. Seu P, Winston DJ, Holt CD, Kaldas F, Busuttil RW. Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors. Transplantation 1997; 64: 1614.
25. Mutimer DJ, Shaw J, O'Donnell K, Elias E. Enhanced cytomegalovirus viral replication after transplantation for fulminant hepatic failure. Liver Transpl Surg 1997; 3: 506.
26. Pillay D, Charman H, Burroughs AK, Smith M, Rolles K, Griffiths PD. Surveillance for CMV infection in orthotopic liver transplant recipients. Transplantation 1992; 53: 1261.
27. Portela D, Patel J, Larson-Keller JJ, et al. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. J Infect Dis 1995; 171: 1014.